Year 2 of Arno’s Commercial Readiness Program

Work on our Arno Compensation-Free Flow Cytometer system is progressing at full speed following the reauthorization of the SBIR program last spring.

The Arno is our 22-color analyzer that uses Time-Resolved Flow Cytometry (TRFC) and fluorescence lifetime discrimination rather than conventional spectral unmixing or compensation. It has no technical equivalent and represents a highly innovative solution, supported by a portfolio of 13 patents to date.

Following a period of significant uncertainty surrounding the Small Business Innovation Research (SBIR) program, we are delighted to be back on track and moving forward with this important effort.

Our Commercialization Readiness Program grant provides support for the continued development of the Arno and the work needed to prepare it for market launch. We remain deeply grateful to the The National Institutes of Health (NIH), and specifically the National Institute of General Medical Sciences (NIGMS), for their continued investment and commitment to advancing innovative research and development and helping bring promising platform technologies to market.